APOA1 and benign neoplasm: To summarise the main results of this study44, a diagnostic performance of the biomarker combinations for differentiation of benign tumours (n = 103) vs. OEC (n = 61) compared to ROMA is shown in Table 3 and Table 4, the results of predictive statistics for ROMA and the combination of CA125, HE4, YKL-40, transthyretin, ApoA1, Beta 2-microglobulin, transferrin, LPA and menopausal status (8-marker assay) for OEC versus benign disease at a specificity level of ~75% are shown.